Oncogenic Determinants Of The Immune Response In Acute Myeloid Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$588,144.00
Summary
There is an urgent need to develop new therapies for patients with AML. We have shown that the body's own immune system can target certain types of AML. We will determine how these types of AML change to escape control from the immune system and how this can be reversed to re-engage the anti-AML immune response. Using patient samples, we will determine how the anti-AML immune response changes during the course of standard therapy in order to best combine it with immune-targeted therapies.
Determining The Molecular Basis Of Therapy Resistance Conferred By Genetic Lesions In The Tumour Protein TP53 In Haematological Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$885,183.00
Summary
Blood cancers that have genetic lesions in a tumour suppressor protein called TP53 respond poorly to therapy. Curing these patients is extremely challenging and new therapeutic strategies are desperately needed. Here, we aim to uncover the molecular mechanisms of drug resistance caused by loss of TP53 function and rationally design new therapies that may be curative. To do this, our team of leading scientists and clinicians will study patient samples and pre-clinical models of blood cancer.